Program
HN2301
A development code. Also written as “HN2301 injection”.
Its studies are mostly in Myasthenia Gravis · Lupus Erythematosus, Systemic, led by Shenzhen MagicRNA Biotechnology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen MagicRNA Biotechnology | 32 open or running | phase 1since Jan 15, 2025 | Jan 15, 2025 | May 31, 2027phase 1 · NCT07556120 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06801119 · 30 planned · China
- Apr 29, 2025No phase study in Myasthenia GravisNCT06965309 · 9 enrolled · China
- Apr 16, 2026Phase 1 study in Myasthenia GravisNCT07556120 · 6 planned · China
Ahead
- May 31, 2027Primary completion: phase 1 study in Myasthenia GravisNCT07556120
- Dec 31, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06801119
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07556120Myasthenia Gravis · China | 1 | Not yet recruiting | May 31, 2027 | 6 |
| NCT06965309Myasthenia Gravis · China | – | Terminated | Feb 11, 2026 | 9 |
| NCT06801119Lupus Erythematosus, Systemic · China | 1 | Recruiting | Dec 31, 2027 | 30 |
How it is read
Names in the registry
- “HN2301 injection”, 3 entries
Codes read as this program: HN2301.
Conditions, from the studies’ own filings
- Myasthenia Gravis, 2 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.